Healthwell Acquisition Corporation I News - HWEL

Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate

Healthwell Acquisition Corp. I (“Healthwell”) (Nasdaq: HWEL) announced today that (i) its previously announced special meeting of stockholders...

Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.

Healthwell Acquisition Corp. I (“Healthwell”) (Nasdaq: HWEL) announced today that its previously announced Business Combination Agreement in...

Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions

Healthwell Acquisition Corp. I (“Healthwell,” “HWEL” or the “Company”) (NASDAQ: HWEL) announced today that it has postponed until further...

Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions

Healthwell Acquisition Corp. I (“Healthwell,” “HWEL” or the “Company”) (NASDAQ: HWEL) announced today that it has postponed the date of the...

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

Dosing comes three weeks after the first site opened Full enrollment of six patients is expected to take 10 months, conducted in up to three...

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Site activation comes...

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

Nash Gabrail, MD of the Gabrail Cancer Center to be lead investigator Start-up services are underway with patient enrollment planned for Q4 2023...

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 ________________ SCHEDULE 14A ________________ Proxy...

Current Report Filing (8-k)

0001845013 false 0001845013 2023-06-13 2023-06-13 0001845013...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Current Report Filing (8-k)

0001845013 false 0001845013 2023-06-12 2023-06-12 0001845013...

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

FDA agrees to the planned Phase 1b study in second-line transplant-ineligible patients in multiple myeloma Treatment regimen will include...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No...

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Healthwell Acquisition Corporation I (HWEL)

Empower your portfolio: Real-time discussions and actionable trading ideas.

HWEL News

Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate

Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.

Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions

Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Current Report Filing (8-k)

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

Statement of Ownership (sc 13g)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

HWEL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Healthwell Acquisition Corporation I (HWEL) News

Healthwell Acquisition Corporation I (HWEL)

Empower your portfolio: Real-time discussions and actionable trading ideas.

HWEL News

Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate

Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.

Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions

Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

Current Report Filing (8-k)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Current Report Filing (8-k)

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

Statement of Ownership (sc 13g)

Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

HWEL Discussion

Your Recent History